Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | PYGB | P11216 | 1/20 | 0.37 |
| ▸ | AMY2A | P04746 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.33 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13223240 | 1.00 | LGALS8 (0.39) | LGALS8SLC2A1OGAPYGBAMY2A | |
| SCHEMBL25735655 | 0.93 | AMY2A (0.40) | LGALS8SLC2A1OGAPYGBAMY2A | |
| SCHEMBL8960162 | 0.93 | AMY2A (0.40) | LGALS8SLC2A1OGAPYGBAMY2A | |
| SCHEMBL5304856 | 0.93 | AMY2A (0.40) | LGALS8SLC2A1OGAPYGBAMY2A | |
| SCHEMBL8960157 | 0.93 | AMY2A (0.40) | LGALS8SLC2A1OGAPYGBAMY2A | |
| SCHEMBL29072889 | 0.93 | AMY2A (0.40) | LGALS8SLC2A1OGAPYGBAMY2A | |
| SCHEMBL3991601 | 0.87 | AMY2A (0.43) | LGALS8SLC2A1OGAPYGBAMY2A | |
| SCHEMBL13243211 | 0.87 | LGALS8 (0.46) | LGALS8SLC2A1OGAPYGBMAPK1 | |
| SCHEMBL22511423 | 0.87 | LGALS8 (0.46) | LGALS8SLC2A1OGAPYGBMAPK1 | |
| SCHEMBL22073978 | 0.87 | LGALS8 (0.46) | LGALS8SLC2A1OGAPYGBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161598-A1 | Compositions and methods for treatment of disease with acetylated disaccharides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161598-A1 | Compositions and methods for treatment of disease with acetylated disaccharides | ASAH2, ALG1, MAN2B1 | LGALS8 456/4885SLC2A1 395/4885OGA 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.